Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived XenograftsShunqiang Li, Ana M. González-Angulo, Jingqin Luo et al.|Cell Reports|2013Cited by 630
Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast CancerX. Cynthia, Matthew J. Ellis, Ron Bose et al.|Clinical Cancer Research|2017Cited by 191
Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2<sup>mut</sup> MBC).X. Cynthia, Matthew J. Ellis, Ron Bose et al.|Journal of Clinical Oncology|2016Cited by 17
Supplementary Table S4 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast CancerX. Cynthia, Matthew J. Ellis, Feng Gao et al.|Unknown|2023Cited by 0
Supplementary Tables S1 and S2 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast CancerX. Cynthia, Matthew J. Ellis, Feng Gao et al.|Unknown|2023Cited by 0